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patients is poor. In addition, the study demonstrated that the risk of refracture is 
associated with the compliance and persistence with bisphosphonate therapy in 
Taiwan. The compliance and persistence issues for osteoporosis treatment warrant 
much more attention. 
MUSCULAR-SKELETAL DISORDERS – Cost Studies
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OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization in patients with rheumatoid arthritis (RA). 
METHODS: Patients’ self-reported data were collected from 2009 National Health 
and Wellness Survey (NHWS). Survey samples represented major urban areas in 
China. QOL was measured by the physical component score (PCS) and mental com-
ponent score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general popu-
lation). Loss of work/productivity was measured by the validated Work Productivity 
and Activity Impairment (WPAI) instrument. Medical resource utilization was mea-
sured by health-care provider, emergency room (ER) visits and hospitalization in the 
past 6 months. Comparisons were made between respondents who suffer from RA 
(excluding psoriasis, psoriatic arthritis, or inﬂ ammatory bowel disease) versus respon-
dents without RA (non-RA group). RESULTS: Of the 13,307 survey respondents, 276 
(2.1%) were diagnosed with RA, and the average age was 46.6 years. There were 
more females in RA group (59.5%) versus non-RA group (50.7%). RA group reported 
more diagnosed comorbidities (insomnia 43%, hypertension 24.7%, migraine 24.1%, 
allergies 23.4%, arrhythmia 22.8%, gingivitis 22.5%, dermatitis 18.9%, osteoporosis 
16.9%, anemia 15.5%, bronchitis 13.9%, asthma 13.7%), lower mean scores of PCS 
(42.7 ` 48.5) and MCS (42.4 vs. 46.0), more patients visited health-care providers 
(83.3% vs. 56.3%), ER (48.5% vs. 18.9%) and hospitalized (25.0% vs. 7.0%) in the 
past 6 months compared to non-RA group. Also, RA group reported 37.8% work/
productivity loss (absenteeism and presenteeism) and 36.6% impairment in daily 
activity compared to 22.7% and 22.6% in non-RA group. All comparisons between 
RA and non-RA groups were statistically signiﬁ cant at P < 0.05. CONCLUSIONS: 
From the China NHWS results, RA patients suffer from impairment in quality of life, 
work/productivity loss, more comorbidities and use of medical services. The ﬁ ndings 
indicate there is still an unmet medical need in RA patients in China. 
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OBJECTIVES: In the Judo-therapeutic ﬁ eld, their costs are partly covered by National 
Health Insurance System via fee-for-service reimbursement, which does not necessarily 
reﬂ ect actual costs. Therefore, the actual situation of medical practice in Judo-therapy 
Clinics (bone-setting clinics) is analyzed by comparison between the actual costs cal-
culated by micro-costing methods and .reimbursement cost calculated by fee-for-
service system. METHODS: The basis of this study is a bidirectional evaluation of 
single medical intervention in terms of actual cost and reimbursed cost for single 
treatment with following methods: 1) All receipts are collected from the participating 
bone-setting clinics for a ﬁ xed period of time; 2) Along with collection of receipts, 
information on the medical interventions is recorded by region with regard to “how 
long” and “who” performed them; 3) The tentative cost of medical intervention is 
calculated based on the data in 2) above and the data of wage for the engaged persons. 
In other words, the tentative cost is calculated as the practitioner’s wage per unit time 
multiplied by the time consumed; 4) The cost-based amount of individual medical 
intervention is calculated by adding indirect costs (wage for other staff than practitio-
ner, cost for operation/maintenance of judo-therapy clinic) to the data in 3); and 5) 
Standard critical paths are made for several diseases, based on which medical expense 
for each therapy model is calculated in terms of both receipt-based amount and cost-
based amount, and a comparison of amount is made between them. RESULTS: 
Therapies in a total of 1646 regions were recorded, based on which a comparison was 
made using four diseases (lumbar sprain, neck sprain, femoral contusion, back contu-
sion) as models. The receipt-based medical expense was JPY9030 (US$100) for all 
diseases, while the cost-based medical expense widely varied from JPY22,057 to 
JPY22,950 (US$245 to US$255). CONCLUSIONS: There was a signiﬁ cant difference 
between the insurance beneﬁ t amount and the actual cost of medical intervention in 
judo-therapy. 
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OBJECTIVES: Facing scarce data in Thailand on hospital costs of osteoporotic frac-
tures, we examined repeated fractures and hospital costs incurred over 1 year from a 
primary osteoporotic hip fracture hospitalization occurred in postmenopausal women 
with or without comorbidities at Bumrungrad International Hospital in Bangkok. 
METHODS: Hospital admissions for primary hip fracture coded ICD-10 S 72.1 in 
post-menopausal women, aged 55 or older, were collected from January 2007 to 
January 2009. The hip fracture comorbidities considered were hypertension, type 2 
diabetes, cardiovascular disease and their combinations. The repeated fractures within 
6 or 12 months after ﬁ rst admission were documented. All direct medical costs were 
retrieved from the hospital database looking at 1-year follow-up period. Statistical 
analysis employed unpaired t-test, Mann–Whitney U test and multivariate analysis for 
comparison of outcomes, costs and correlations to comorbidities. RESULTS: A total 
of 59 hospital admissions for diagnosed osteoporotic primary hip fracture in post-
menopausal women were screened. Patients’ mean age (SD) was 74.6 (7.7) years old, 
the mean hospital follow-up (SD) was 246.7 (77.5) days and the mean hospitalization 
duration (SD) was 17.0 (12.2) days. Patients at screening with and without comorbidi-
ties had similar characteristics including the types of fractures. The group with comor-
bidities was at higher relative risks of repeated fractures at 6 and 12 months follow-up 
compared to the group without comorbidities (1.13 vs. 0.91, P = 0.016; 1.10 vs. 0.94, 
P = 0.273, respectively) with consequently higher health-care utilization cost with 
564,300 THB/patient/year versus 374,200 THB/patient/year, P = 0.043. The cost of 
all type drugs for both groups was only 8–10% of the total illness cost. CONCLU-
SIONS: In osteoporotic post-menopausal women admitted at hospital for primary hip 
fracture, comorbidities increased risks of repeated fractures hospitalization as well 
as hospital costs. The cost of drugs was marginal among hospital costs of 
osteoporosis. 
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OBJECTIVES: To evaluate the cost-effectiveness of bisphosphonates (alendronate, 
risedronate, ibandronate, zoledronic acid), raloxifene, calcitonin and strontium 
ranelate, with a combination of calcium and Vitamin D as comparator, for the preven-
tion of osteoporosis-related fractures in Thai post-menopausal women. METHODS: 
A Markov state transition model with 1-year cycle length was designed to simulate 
the cost-effectiveness of seven osteoporosis treatment interventions, compared with 
calcium and vitamin D, in Thai post-menopausal women aged 50–70 years. The model 
health states were categorized as osteopenia/no fracture, hip fracture, vertebral frac-
ture, post-hip fracture, post-vertebral fracture and death. Treatment effects were 
obtained from published literature. The analysis was conducted using a societal per-
spective and included direct medical, direct nonmedical and indirect costs. Uncertainty 
was investigated by a probabilistic Monte Carlo simulation. Treatment outcomes were 
measured in terms of number of fractures avoided, number of life-years gained and 
quality-adjusted life-years (QALY) gained. Cost-effectiveness was deﬁ ned as an ICER 
of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of 
no fracture for 1 year). RESULTS: 1) For patients with no prior fracture (primary 
prevention), zoledronic acid is cost-effective at ≥65 years, alendronate, risedronate and 
ibandronate at ≥70 years. 2) For patients with prior vertebral fracture (secondary 
prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and 
ibandronate at ≥55 years, raloxifene and strontium ranelate at ≥60 years; and 3) For 
patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥60 
years, alendronate at ≥65 years, and risedronate and ibandronate at ≥70 years. CON-
CLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most cost-
effective treatment option for both primary and secondary fracture prevention in Thai 
postmenopausal women with osteoporosis. These ﬁ ndings should be implemented in 
the government policy for selecting appropriate anti-osteoporotic drugs and reim-
bursement support strategy for Thai postmenopausal women with osteoporosis. 
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OBJECTIVES: We sought to determine, from the Australian health-care perspective, 
the cost-effectiveness of the bisphosphonate risedronate, relative to placebo, in pre-
venting vertebral fractures among patients with corticosteroid-induced osteoporosis. 
METHODS: A decision-analytic Markov model was developed to simulate the onset 
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of vertebral fractures and death among Australian patients with corticosteroid-induced 
osteoporosis. Age-speciﬁ c underlying incidences of vertebral fractures and death were 
estimated from published data. The costs (AUD $1393 in Year 1 and AUD $34 in 
subsequent years) and utility (0.71) associated with a vertebral fracture were also 
drawn from published sources, as was the efﬁ cacy of risedronate in reducing vertebral 
fracture risk (relative risk 0.43, 95% CI 0.20–0.92). The model adopted a life-time 
horizon and an annual discount rate of 5% was applied to both costs and years of 
life/QALYs lived. Multiple sensitivity analyses were undertaken with reasonable varia-
tions to key data inputs. RESULTS: The base-case incremental cost-effectiveness ratio 
(ICER) with a life-time horizon was AUD $18,085 per QALY saved. Estimated ICERs 
remained below AUD $40,000 per QALY saved throughout all sensitivity analyses, 
except when assuming the upper limit of the 95% conﬁ dence interval for risedronate’s 
efﬁ cacy in reducing vertebral fracture risk (AUD $53,130 per QALY saved). CON-
CLUSIONS: Risedronate represents a cost-effective option for preventing vertebral 
fractures in Australian patients with corticosteroid-induced osteoporosis. This was 
conﬁ rmed by the recent recommendation by the Australian Pharmaceutical Beneﬁ ts 
Advisory Committee (PBAC) that risedronate be reimbursed for this indication. 
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OBJECTIVES: Rheumatoid arthritis (RA) is a multisystem disease with various extra-
articular manifestations (EAMs). Health-related quality of life (HRQOL) issues are 
assuming increasing importance in chronic rheumatic diseases like RA. Very less data 
on QOL in RA is available from the Indian subcontinent. There is also a paucity of 
literature on the impact of EAMs on HRQOL in RA. The objective of this study was 
to address these lacunae. METHODS: The study group comprised 166 patients with 
RA from a rheumatology clinic in India. Quality of life was estimated by the generic 
HRQOL measure: World Health Organization quality of life instrument (WHOQOL-
Bref). Disease activity in RA was measured by calculating Disease Activity Score-28 
(DAS28) and functional disability by the Health Assessment Questionnaire (HAQ). 
Extra-articular manifestations (EAMs) were diagnosed clinically. RESULTS: The 
mean duration of rheumatoid arthritis (RA) was 10 ± 3.1 years. The mean DAS28 
and HAQ were 4.21 ± 1.1 and 1.01 ± 1.2, respectively. At least one ExRA was present 
in 46 patients. The mean HRQOL scores of the patients were 11.5 +/− 2.1, 12.2 
+/− 2.5, 13.4 +/− 2.6, and 12.3 +/− 2.4 in the physical, psychological, social, and 
environmental domains of the WHOQOL-Bref respectively. Age, gender, disease dura-
tion, educational status, constitutional symptoms, rheumatoid factor positivity, ero-
sions and deformities did not inﬂ uence HRQOL. Disease activity had a negative 
inﬂ uence on the physical and psychological domains. Patients with EAMs had signiﬁ -
cantly higher DAS28 scores compared to patients without EAMs. Even after adjust-
ment for disease activity, patients with EAMs had lower HRQOL scores than patients 
without these features (statistically signiﬁ cant for physical domain). CONCLUSIONS: 
The physical domain of HRQOL is most affected in Indian patients with RA. Increas-
ing disease activity and presence of EAMs worsens the quality of life. 
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OBJECTIVES: The purpose of this study was to describe the pattern of health-care 
utilization among new patients with low back pain. METHODS: This study is based 
on the Korean National Health Insurance (NHI) claim data. Study subjects included 
those who 1) were newly diagnosed as low back pain; 2) received at least one lum-
bosacral spine simple x-ray; and 3) were not using medical service as a patient with 
low back pain for past 2 years before the ﬁ rst visit (index date). The follow-up period 
was 1 year from the index date. RESULTS: New patients with low back pain used 
the clinic (81.8%) most and orthopedics (62.2%) was the most visited department in 
2006. Ninety-six percent of new patients used outpatient service and 5.9% used 
inpatient service. The medical cost (paid by insurers) per patient was $215.1. Male 
expenses more than female, and the cost increased as the age of patients increased. 
Average days including medication days and days of visit per new patient with low 
back pain was 6.7 days with the tendency that female’s average days including medica-
tion days and days of visit were more than those of male’s. In terms of outpatient 
service, average days including medication days and days of visit per new patients was 
5.8 days and in inpatient service, it was 15.8 days. CONCLUSIONS: Efforts to 
identify the factors which may produce low back pain and to reduce the incidence is 
on need. Also, analysis on the factors inﬂ uential over the health-care use of new 
patients with low back pain needs to be conducted in future studies. 
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OBJECTIVES: The objectives of this study were 1) to identify the pattern of health-
care use; and 2) to estimate the pattern change of health-care use for low back pain 
in each year of 2006, 2007, and 2008. METHODS: This study is based on the Korean 
National Health Insurance (NHI) claim data. Study subjects included those who 1) 
used medical service as a patient with low back pain from January 1 to December 31, 
and 2) received at least one lumbosacral spine simple x-ray each year. The identiﬁ ed 
number of the patients was 1,981,427 in 2006, 2,069,995 in 2007, and 2,119,408 in 
2008. RESULTS: Patients with low back pain used the clinic most and orthopedics 
was the most visited department in each year of 2006, 2007, and 2008. The rate of 
outpatient service use declined and that of inpatient service use increased in compared 
3 years. The medical cost (paid by insurers) showed increasing trend estimated as $569 
million in 2006, $626 million in 2007, and $654 million in 2008. However, if the 
inﬂ ation rate of consumer price was considered (2.4% going up between 2006 and 
2007, and 7.3% between 2006 and 2008), the cost in 2007 was estimated as $611 
million still showing increase, but, in 2008, $610 million was estimated showing 
decrease. Medical cost per patient was $287.2 in 2006, $295.2 in 2007, and $287.8 
in 2008. Average days including medication days and days of visit per patient was 9.4 
days in 2006, 9.1 days in 2007, and 8.8 days in 2008 as declining. CONCLUSIONS: 
Efforts are needed to reduce prevalence and incidence of low back pain. And analysis 
on factors inﬂ uential on the medical use of the patients needs to be conducted in future 
studies. 
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OBJECTIVES: The purposes of this study were 1) to analyze the pattern of injection 
therapy use for low back pain, and 2) to estimate the health-care use of low back pain 
patient who received injection therapy in 2006, 2007, and 2008. METHODS: This 
study is based on the Korean National Health Insurance (NHI) claim data. Study 
subjects included those who 1) used medical service as a patients with low back pain 
from January 1 to December 31; 2) received at least one lumbosacral spine simple 
x-ray; and 3) took more than one injection therapy each year. RESULTS: The percent 
of patients with low back pain who received injection therapy was increasing as fol-
lowed: 10.8% in 2006 (213,796 among total 1,981,427 patients with low back pain), 
11.0% in 2007 (227,432 among 2,069,995), and 11.5% (244,640 among 2,119,408). 
Number of patients with low back pain treated with injections per 100,000 general 
population was 436 in 2006, 462 in 2007, and 494 in 2008. Number of patients with 
low back pain treated with injections per 100,000 low back pain patients was 10,790 
in 2006, 10,987 in 2007, and 11,543 in 2008. The rate of patients who received one 
injection in a year was 58.9% in 2006, 52.5% in 2007, and 48.1% in 2008 showing 
tendency of decrease, while more than two injections was increasing. The most con-
ducted procedure was Epidural Nerve Blocks consistently for 3 years. The most 
department visited for service was anesthesiology in 2006 and orthopedics in 2007 
and 2008. CONCLUSIONS: The injection therapy on patients with low back pain is 
increasing. But the efﬁ cacy of it has not reached to consensus so far, which means 
more careful conducting is needed. Also, the efﬁ cacy of injection therapy speciﬁ cally 
in South Korea should be investigated in future studies. 
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OBJECTIVES: Oral Oxicam and Coxibs’ expenditure at a Thai teaching hospital was 
rapidly increased in recent years. We examined price and quantity factors that inﬂ u-
enced the rising expenditure by deterministic model. METHODS: This study was a 
retrospective database analysis at a Thai teaching hospital in Bangkok. Prescription 
utilization data of one oral Oxicam and two Coxibs (Meloxicam, Celecoxib, and 
Etoricoxib) during ﬁ scal year 2006 to 2009 were retrieved. In the model, changes in 
annual expenditure were attributed to two factors: cost per patient per year (P) and 
number of patients per year (Q). By measuring quantity as Deﬁ ned Daily Dose (DDD), 
changes in cost per patient (P) comprised of two parts: cost per DDD (p) and DDD 
per patient (q). RESULTS: Overall expenditure of the three drugs was risen from 49.9 
million Baht in 2006 to 64.9 million Baht in 2009 (adjusted for inﬂ ation). Thirty 
percent of total increase in expenditure was mainly the result of switching from 
Meloxicam (percent change, −44%) to Etoricoxib (119%). When decomposed into 
price and quantity factors, quantity had more effect than price, especially number of 
patients who moved from Meloxicam (percent change of Q, −35%) to Etoricoxib 
(112%) and Celecoxib (8%). DDD per patient for Celecoxib was a little increase 
(percent change of q, 4%), slightly decreased for Etoricoxib (−4%), and much lower 
for Meloxicam (−32%). Percent change in price of the three drugs was slightly positive 
(28%, 7%, and 8% for Meloxicam, Celecoxib, and Etoricoxib, respectively). CON-
CLUSIONS: The major increase of drug expenditure from 2006 to 2009 was from 
